Targeted Cancer Therapies Linked to Distinct Gastrointestinal Toxicity Patterns
New research from the University of Missouri-Columbia reveals that targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, cause distinct patterns of gastrointestinal injury that are often underrecognized.
A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled "Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection." First author Muhammad Moseeb Ali Hashim and co-corresponding author Kamran Zahoor from the University of Missouri-Columbia examined how targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, affect the gastrointestinal tract.
The authors analyzed clinical trials, FDA drug labels, national safety databases, and pathology reports. Their findings show that these therapies can cause distinct and sometimes serious digestive injuries that are often underrecognized. Greater awareness may support earlier diagnosis, better treatment decisions, and improved patient protection.
Targeted therapies have transformed care for colorectal cancer, gastric cancer, liver cancer, and gastrointestinal stromal tumors. By focusing on specific molecular targets, these drugs offer more precise treatment than traditional chemotherapy. However, they can also harm healthy tissue in the digestive system, making gastrointestinal toxicity an important clinical concern as their use expands.
The authors outline how different drug classes produce different patterns of injury. Tyrosine kinase inhibitors may reduce blood vessel growth in the gut, leading to diarrhea, abdominal pain, bleeding, or, in rare cases, bowel perforation. TKIs primarily exert vascular compromise by inhibiting kinases involved in angiogenesis, notably vascular endothelial growth factor (VEGF) pathways. This mechanism disrupts mucosal blood supply, precipitating ischemic injuries.
Antibody-drug conjugates, designed as cytotoxic payload-delivering molecules conjugated to monoclonal antibodies, exert direct epithelial toxicity upon uptake by intestinal epithelial cells. This leads to mucosal ulceration, colitis, and manifestations including nausea, vomiting, mouth sores, and stomatitis.
CAR-T cell therapy may trigger widespread immune-related inflammation that also affects the gastrointestinal tract. The intense systemic inflammatory milieu triggered by CAR-T cells affects the gut via widespread immune-mediated inflammation, often mimicking infectious or autoimmune enteropathies, primarily mediated through cytokine release syndrome.
These side effects can resemble infections, inflammatory bowel disease, or reduced blood flow to the intestine. Biopsy samples may show cell death, ulceration, or inflammation, which can be misinterpreted without a clear treatment history. Pathologists play a crucial role in discerning treatment-related changes, which may include apoptotic crypt cell death, mucosal ulcerations, or immune cell infiltrates, all in the context of a patient's oncologic regimen and clinical presentation. The authors highlight the importance of close collaboration between oncologists, gastroenterologists, and pathologists to ensure accurate diagnosis.
The paper also discusses national safety monitoring systems such as the FDA Adverse Event Reporting System, which tracks reported gastrointestinal complications linked to these therapies. The study highlights that reported GI toxicities in the FAERS database correspond with the clinicopathologic observations and drug label warnings, reinforcing the validity of their findings. Combining clinical findings with pathology data and regulatory safety information can strengthen drug monitoring and enhance patient safety nationwide.
Looking toward the future, the review identifies several critical research gaps impeding progress. There is a paucity of real-world histopathologic correlation studies that would illuminate the full clinical spectrum and outcomes of GI toxicities outside clinical trial settings. Additionally, the role of the gut microbiome in modulating toxicity severity and therapeutic response remains an emerging frontier. Advanced digital health technologies, including patient-reported outcome measures and integrated pharmacovigilance platforms, also hold promise in bridging these knowledge gaps.
By integrating clinical, pathological, and regulatory perspectives, this research offers a practical framework for recognizing and managing gastrointestinal toxicity associated with targeted cancer therapies. As precision oncology advances, coordinated care and informed monitoring will remain essential to keep these treatments both effective and safe.